Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2025 Jul 31;14(7):2374-2382.
doi: 10.21037/tlcr-2025-463. Epub 2025 Jul 22.

KRAS and STK11 co-mutations in resectable non-small cell lung cancer: enduring prognostic value and impaired immunotherapy response

Luisana Sisca  1   2 , Priscilla Cascetta  3 , Ayesha Aijaz  4 , Chiara Catania  3 , Francesco Facchinetti  5 , Abdul Rafeh Naqash  4 , Biagio Ricciuti  5 , Alessio Cortellini  1   2   6
Affiliations
Editorial

KRAS and STK11 co-mutations in resectable non-small cell lung cancer: enduring prognostic value and impaired immunotherapy response

Luisana Sisca et al. Transl Lung Cancer Res. .
No abstract available

Keywords: KRAS; Non-small cell lung cancer (NSCLC); STK11; immunotherapy; tumor microenvironment.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://tlcr.amegroups.com/article/view/10.21037/tlcr-2025-463/coif). F.F. receives speaker fees from Roche. A.R.N. receives honoraria from NGM Biopharmaceuticals; consulting fees from Foundation Medicine, Astellas Pharma, and Natera; research funding to his institution from Loxo/Lilly, Surface Oncology, ADC Therapeutics, IgM Biosciences, EMD Serono, Aravive, NiKang Therapeutics, Revolution Medicines, Jazz Pharmaceuticals, Immunocore, Phanes Therapeutics, Kymera, Inspirna, and AbbVie; and support for travel, accommodations, and expenses from Foundation Medicine, Binaytara Foundation, Society for Immunotherapy of Cancer, ASCO, American Society for Radiation Oncology, IDEOlogy Health, and Jazz Pharmaceuticals. B.R. serves as a consultant/advisory board member for AMGEN, Regeneron, AstraZeneca, and Capvision; and receives speaker fees from AstraZeneca; honoraria from Targeted Oncology and the Society for Immunotherapy of Cancer; and travel support from Bristol-Myers Squibb and Genentech. A.C. receives consulting fees from Bristol-Myers Squibb, AstraZeneca, MSD Oncology, Regeneron, Amgen, Daiichi Sankyo/AstraZeneca, Roche, Access Infinity, Ardelis Health, IQVIA, Alpha Sight, Capvision, techspert.io, Atheneum, Alira Health, Tegus, and Johnson & Johnson/Janssen; honoraria from AstraZeneca, MSD Oncology, Sanofi/Regeneron, Roche, and Johnson & Johnson/Janssen; research funding (to institution) from the International Association for the Study of Lung Cancer; travel support (travel, accommodations, expenses) from Roche and MSD Oncology; and has other personal relationships with MSD Oncology, Bristol-Myers Squibb, and GSK. The other authors have no conflicts of interest to declare.

Figures

Figure 1
Figure 1
Visual summary of the clinical workflow and main translational insights, highlighting the key steps and findings across the study by Rosner et al. (A) Influence of KRASmut vs. KRASwt on outcomes to neoadjuvant ICI administration. (B) Influence of KRASmut/STK11mut vs. KRASmut/STK11wt on outcomes to neoadjuvant ICI administration. CD8+ TIL, CD8+ tumor-infiltrating lymphocyte; ICIs, immune checkpoint inhibitors; IL-2, interleukin-2; KRAS, Kirsten rat sarcoma viral oncogene homolog; MPR, major pathological response; mRFS, median recurrence-free survival; mut, mutation; NSCLC, non-small cell lung cancer; PGE2, prostaglandin E2; pCR, complete pathological response; RFS, recurrence-free survival; STK11, serine/threonine kinase 11; wt, wild type.
See this image and copyright information in PMC

Comment on

References

    1. Felip E, Altorki N, Zhou C, et al. Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial. Lancet 2021;398:1344-57. 10.1016/S0140-6736(21)02098-5 - DOI - PubMed
    1. Wakelee H, Liberman M, Kato T, et al. Perioperative Pembrolizumab for Early-Stage Non-Small-Cell Lung Cancer. N Engl J Med 2023;389:491-503. 10.1056/NEJMoa2302983 - DOI - PMC - PubMed
    1. Pradhan M, Chocry M, Gibbons DL, et al. Emerging biomarkers for neoadjuvant immune checkpoint inhibitors in operable non-small cell lung cancer. Transl Lung Cancer Res 2021;10:590-606. 10.21037/tlcr-20-573 - DOI - PMC - PubMed
    1. Skoulidis F, Li BT, Dy GK, et al. Sotorasib for Lung Cancers with KRAS p.G12C Mutation. N Engl J Med 2021;384:2371-81. 10.1056/NEJMoa2103695 - DOI - PMC - PubMed
    1. Resources for Information | Approved Drugs. FDA grants accelerated approval to adagrasib for KRAS G12C-mutated NSCLC. FDA [Internet]. 2022 Dec 12 [cited 2025 Apr 5]; Available online: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grant...